Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Sanofi's Frexalimab Phase 2 Data Shows 41% Reduction In Key Biomarker Of Nerve Cell Damage In Relapsing MS; High-Dose Arm Demonstrates Significant Drop In Plasma Neurofilament Light Chain Levels After 48 Weeks; Supports Potential As High-Efficacy, Disease-Modifying Treatment; Phase 3 Studies Underway

Author: Benzinga Newsdesk | June 28, 2024 11:41am

Frexalimab new phase 2 data showed reduction of key biomarker of nerve cell damage in relapsing MS

  • Frexalimab high-dose arm observed a 41% reduction in plasma neurofilament light chain (NfL) levels, a biomarker of nerve cell damage, after 48 weeks of treatment
  • Data support potential as a first-in-class, high-efficacy, and disease-modifying treatment for people with relapsing MS
  • Phase 3 studies of frexalimab in relapsing MS and non-relapsing secondary progressive MS (nrSPMS) are underway

https://www.sanofi.com/fr/media-room/communiques-de-presse/2024/2024-06-28-15-30-00-2906026

Posted In: SNY


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

07/05/2024 AXT, Inc. (AXTI)
07/05/2024 Altimmune, Inc. (ALT)
07/09/2024 Li Auto Inc. (LI)
07/12/2024 Inari Medical, Inc. (NARI)
07/12/2024 Sprout Social, Inc. (SPT)
07/15/2024 UnitedHealth Group Inc. (UNH)
07/16/2024 Teladoc Health, Inc. (TDOC)
07/16/2024 Vestis Corporation (VSTS)
07/22/2024 Cambium Networks Corporation (CMBM)
07/22/2024 Biogen Inc. (BIIB)

NEW CASE INVESTIGATION

Ooma Inc (OOMA) AnaptysBio Inc (ANAB)
CORE Finalist